Company: CORT
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001628280-25-048841
Chunk: 38

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 8
Chunk 38
---
 as follows:September 30,2025December 31,2024(in thousands)Cash equivalents$100,392 $98,436 Short-term marketable securities296,544 255,669 Long-term marketable securities102,557 219,831 Total marketable securities$499,493 $573,936 The following table presents our available-for-sale securities grouped by asset type: Fair ValueHierarchyLevelSeptember 30, 2025December 31, 2024Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value  (in thousands)Corporate bondsLevel 2$324,328 $843 $(12)$325,159 $373,440 $333 $(529)$373,244 Commercial paperLevel 26,982 — — 6,982 9,771 6 (2)9,775 U.S. government agency securitiesLevel 226,998 4 — 27,002 7,999 — (2)7,997 U.S. Treasury securitiesLevel 139,932 26 — 39,958 84,458 27 (1)84,484 Money market fundsLevel 1100,392 — — 100,392 98,436 — — 98,436 Total marketable securities$498,632 $873 $(12)$499,493 $574,104 $366 $(534)$573,936 We estimate the fair value of marketable securities classified as Level 1 using quoted market prices obtained from a commercial pricing service for these or identical investments. We estimate the fair value of marketable securities classified as Level 2 using inputs that may include benchmark yields, reported trades, broker/dealer quotes and issuer spreads.We periodically review our debt securities to determine if any of our investments is impaired due to the issuer’s poor credit or other reasons. If the fair value of our investment is less than our amortized cost, we evaluate quantitative and subjective factors – including, but not limited to, the nature of the security, changes in credit ratings and analyst reports concerning the security’s issuer and industry, and interest rate fluctuations and general market conditions – to determine whether an allowance for credit losses is appropriate.None of our investments, including those with unrealized losses, are impaired. Unreal